Table 1 Patients, tumour and treatment characteristics
N (%) | Median (range) | |
|---|---|---|
Gender | ||
Male | 15 (50) | |
Female | 15 (50) | |
Age | ||
In years | 71 (36–92) | |
Sizea | ||
≤5 cm | 10 (38) | |
>5 cm | 16 (62) | |
Site | ||
Arm | 3 (10) | |
Hand or wrist | 5 (17) | |
Leg | 16 (53) | |
Ankle or foot | 7 (20) | |
Number of tumours | ||
Unifocal | 24 (80) | |
Multifocal | 6 (20) | |
Disease stage cSCC at presentation | ||
Primary | 18 (60) | |
Recurrent | 10 (33) | |
Metastatic | 2 (7) | |
Concurrent metastasis | ||
None | 25 (83) | |
Lymph node | 3 (10) | |
Distant | 2 (7) | |
Surgical approach | ||
Axillary | 3 (10) | |
Brachial | 6 (20) | |
Femoral | 20 (67) | |
Iliac | 1 (3) | |
Doses | ||
TNFb (mg) | 2 (1–3) | |
Melphalanb (mg) | 60 (25–80) | |
Hospital stay | ||
In days | 6 (1–72) | |
